New group program aims to help schizophrenia patients spot relapse early
NCT ID NCT07327944
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a group psychoeducation program for people with schizophrenia to help them manage relapse and improve functional recovery. Sixty participants will be split into two groups: one receives the program (four 60-minute sessions) and the other does not. Researchers will measure changes in the ability to recognize early warning signs of relapse and overall functioning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relapse Management Group Psychoeducation Program
What this could lead to
If successful, this program could provide a practical, low-cost tool to help people with schizophrenia recognize early warning signs of relapse and improve their daily functioning.
What could go wrong
This is a small, early-stage study with only 60 participants, so results may not apply widely. The program is short (four sessions) and may not produce lasting benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••